Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-SofiaWAR:SPH 66 EV-to-EBIT is 12.84 as of Aug. 12, 2026, which is 31% below its 10-year median of 18.60. GuruFocus rates WAR:SPH with a GF Score™ of 66/100 and a GF Value™ of zł13.24 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 96 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 55.21% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sopharma AD-Sofia's Enterprise Value for the quarter that ended in Mar. 2026 was zł5,231 Mil.
Sopharma AD-Sofia's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł439 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia EV-to-EBIT Related Terms
Sopharma AD-Sofia EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma AD-Sofia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's EV-to-EBIT falls into.
Sopharma AD-Sofia's current Enterprise Value is zł5,642 Mil.
Sopharma AD-Sofia's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł439 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a EV-to-EBIT of 12.84 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sopharma AD-Sofia and its competitors. This is 31% below median its historical median of 18.60. Over the past decade, Sopharma AD-Sofia's EV-to-EBIT has ranged from 10.02 to 28.71. According to the industry distribution chart, Sopharma AD-Sofia ranks #53 out of 96 companies in the Medical Distribution industry, placing it in the top 55.2%.
Is Sopharma AD-Sofia's EV-to-EBIT too high?
Sopharma AD-Sofia's current EV-to-EBIT of 12.84 is 31% below median its 10-year median of 18.60. Over the past 10 years, this metric has ranged from a low of 10.02 to a high of 28.71. The Medical Distribution industry median EV-to-EBIT is 12.01. Sopharma AD-Sofia's value of 12.84 is 7% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #53 out of 96 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #53 out of 96 companies for EV-to-EBIT. This places Sopharma AD-Sofia in the lower half of its industry. The industry median EV-to-EBIT is 12.01. Sopharma AD-Sofia's value of 12.84 is 7% above this benchmark. Historically, Sopharma AD-Sofia's own EV-to-EBIT has ranged from 10.02 to 28.71 over the past decade. While the company's 10-year median is 18.60 vs. the industry median of 12.01, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 12.01, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current EV-to-EBIT of 12.84 is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 12.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current EV-to-EBIT is 12.84, which is 31% below median its own 10-year median of 18.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.24, compared to a current price of zł7.68 — trading 42% below its estimated fair value. The current EV-to-EBIT is 12.84, which is 31% below median its 10-year median of 18.60 and 7% above the Medical Distribution industry median of 12.01. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current EV-to-EBIT is 12.84 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.68 is trading 42% below its estimated GF Value™ of zł13.24.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
EV-to-EBIT: 12.84 (31% below median its 10-year median of 18.60)
GF Value™: zł13.24 vs. price of zł7.68 (42% below fair value)
Industry Position: 7% above the Medical Distribution median (#53 of 96)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score
Get the complete analysis for WAR:SPH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
